BIRMINGHAM, Ala.--(BUSINESS WIRE)--BioDtech, Inc., a biotechnology company engaged in the development of cutting-edge products for the endotoxin market, announced that it has been granted a patent, by the United States patent office (No. 8,349,570), protecting methods of endotoxin detection. The patent, entitled “Enhancing Endotoxin Detection,” covers the company’s EndoPrepTM and ESPTM technologies for the use of accurate endotoxin detection in biopharmaceuticals and human plasma, respectively.
